Abstract
Objective
To investigate the drug interaction potential between itraconazole and nevirapine.
Methods
Our study was conducted in 12 healthy volunteers in two phases. In phase 1 (from days 1–28), all subjects were randomly assigned to a two-way crossover study of a nevirapine regimen (nevirapine 200 mg once daily for 7 days) and an itraconazole regimen (itraconazole 200 mg once daily for 7 days) with a 14-day wash-out period between. Phase 2 (from days 43–49) was performed 14 days after phase 1 ended, and all subjects received a combination regimen (nevirapine 200 mg combined with itraconazole 200 mg once daily for 7 days). Nevirapine pharmacokinetic studies were carried out starting with the seventh dose of nevirapine in the nevirapine regimen (on days 7–10 or 28–31) and the combination regimen (on days 49–52). Itraconazole pharmacokinetic studies were carried out starting with the seventh dose of itraconazole in the itraconazole regimen (on days 7–10 or 28–31) and the combination regimen (on days 49–52).
Results
There was no significant difference in nevirapine pharmacokinetic parameters between the nevirapine and combination regimens. Itraconazole plasma concentrations were lower when it was administered in the combination regimen than when it was administered in the itraconazole regimen. The mean Cmax, AUC0–96 and t 1/2 of itraconazole were significantly reduced by 38, 61 and 31%, respectively.
Conclusion
Nevirapine had a strong inducing effect on the metabolism of itraconazole, but there was no significant effect of itraconazole on the pharmacokinetics of nevirapine. However, a higher daily dosage of itraconazole might have an inhibitory effect.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gazzard B, on behalf of the BHIVA Writing Committee (2005) British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 6(Suppl 2):1–61
Varis T, Kivisto KT, Backman JT, Neuvonen PJ (2000) The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther 68:487–494
Araki K, Yasui-Furukori N, Fukasawa T, Aoshima T, Suzuki A, Inoue Y, Tateishi T, Otani K (2004) Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. Eur J Clin Pharmacol 60:427–430
Olkkola KT, Backman JT, Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481–485
Piscitelli SC, Gallicano KD (2001) Interaction among drugs for HIV and opportunistic infections. N Engl J Med 344:984–996
Murphy RL, Montaner J (1996) Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 5:1183–1199
Loo TW, Clarke DM (2005) Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol 206:173–185
Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ (2002) Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 19:1038–1045
Almond LM, Edirisnghe D, Dalton M, Bonington A, Back DJ, Khoo SH (2005) Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther 78:132–142
Balayssac D, Authier N, Cayre A, Coudore F (2005) Does inhibition of P-glycoprotein lead to drug-drug interaction? Toxicol Lett 156:319–329
Lopez RM, Pou L, Gomez MR, Ruiz I, Monterde J (2001) Simple and rapid determination of nevirapine in human serum by reverse-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 751:371–376
Badcock NR (1990) Micro-scale method for itraconazole in plasma by reversed-phase high-performance liquid chromatography. J Chromatogr 525:478–483
Grant SM, Clissold SP (1989) Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses. Drugs 37:310–344
Ducharme MP, Slaughter RL, Warbasse LH, Chandrasekar PH, Van de Velde V, Mannens G, Edwards DJ (1995) Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther 58:617–624
Albengres E, Le Louet H, Tillement JP (1998) Systemic antifungal agents: drug interactions of clinical significance. Drug Saf 18:83–97
Bottiger Y, Tybring G, Gotharson E, Bertilsson L (1997) Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 62:384–391
Kishimolo W, Takano J, Senda C, Ishiquro N, Sakai K, Iqarashi T (2000) Quantitative prediction of in vitro drug interaction between nevirapine and antifungal agents from in vitro data in rats. Biol Pharm Bull 23:1027–1032
Lamson M, Robinson P, Gigliotti M, Myers MW (1998) The pharmacokinetic interaction of nevirapine and ketoconazole. In: Abstracts of the 12th World AIDS Conference, Geneva, Switzerland, Abstract 12218, p 55
Cartledge ID, Midgely J, Gazzard BG (1997) Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. J Clin Pathol 50:477–480
Acknowledgements
We thank Mr. David Patterson for checking our English. This work was supported by a faculty grant from the Faculty of Medicine, Prince of Songkla University.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jaruratanasirikul, S., Sriwiriyajan, S. Pharmacokinetic study of the interaction between itraconazole and nevirapine. Eur J Clin Pharmacol 63, 451–456 (2007). https://doi.org/10.1007/s00228-007-0280-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-007-0280-x